Provided by Tiger Trade Technology Pte. Ltd.

Aprea Therapeutics, Inc.

0.8711
-0.0090-1.02%
Volume:65.06K
Turnover:57.56K
Market Cap:6.09M
PE:-0.41
High:0.9010
Open:0.8625
Low:0.8200
Close:0.8801
52wk High:2.79
52wk Low:0.5480
Shares:6.99M
Float Shares:4.56M
Volume Ratio:0.58
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1364
EPS(LYR):-2.3519
ROE:-74.72%
ROA:-41.90%
PB:0.56
PE(LYR):-0.37

Loading ...

Aprea Therapeutics Inc - 50% Reduction in Lesion, 90% Decrease in CA-125 in Patient

THOMSON REUTERS
·
Jan 29

Aprea Therapeutics Announces Early Clinical Proof-of-Concept in the Ongoing Acesot-1051 Dose-Escalation Trial Evaluating Wee1 Inhibitor Apr-1051, Including Partial Response Observed on First Scan

THOMSON REUTERS
·
Jan 29

Aprea Therapeutics Inc - Unconfirmed Partial Response at 150 Mg Dose

THOMSON REUTERS
·
Jan 29

Aprea Therapeutics Inc: Additional Updates in First Half of 2026 and Completing Dose Escalation Later in Year

THOMSON REUTERS
·
Jan 29

Aprea Therapeutics Announces $5.6 Million Private Placement Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
Jan 29

Aprea Therapeutics Faces Nasdaq Delisting Risk Over Minimum Bid Price

Reuters
·
Jan 26

U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart

Reuters
·
Dec 22, 2025

Aprea Therapeutics Inc - Files Prospectus for Resale of 5.5 Mln Shares by the Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Dec 20, 2025

Aprea Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $5 From $20

THOMSON REUTERS
·
Dec 19, 2025

BRIEF-Aprea Therapeutics CEO Issues Letter To Shareholders Highlighting Outlook For 2026

Reuters
·
Dec 18, 2025

Aprea Therapeutics Inc - Pauses Enrollment in Aboya-119 Study Monotherapy Arms

THOMSON REUTERS
·
Dec 18, 2025

Director Marc Duey Reports Acquisition of Common Shares in Aprea Therapeutics Inc

Reuters
·
Dec 11, 2025

Aprea Therapeutics CFO John P. Hamill Reports Acquisition of Common Shares

Reuters
·
Dec 11, 2025

Aprea Therapeutics Inc - Net Proceeds Expected to Fund Aprea Into 2027

THOMSON REUTERS
·
Dec 09, 2025

Press Release: Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dow Jones
·
Dec 09, 2025

Aprea Therapeutics Reports Continued Clinical Progress and Extends Cash Runway Into Q4 2026

Reuters
·
Nov 12, 2025

Aprea Therapeutics Advances WEE1 Inhibitor APR-1051 in Phase 1 Trial for Hard-to-Treat Cancers

Reuters
·
Nov 12, 2025

Aprea Therapeutics Inc - Has Cash Runway Into Q4 2026

THOMSON REUTERS
·
Nov 12, 2025

Aprea Therapeutics Q3 Net Income USD -3 Million

THOMSON REUTERS
·
Nov 12, 2025

BRIEF-Aprea Sees Early Activity in APR-1051 Wee1 Trial

Reuters
·
Oct 24, 2025